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Abstract
Prostate cancer gene 3 (PCA3) is a non-coding gene specifically overexpressed in prostate cancer (PCa) that has
great potential as a clinical biomarker for predicting prostate biopsy outcome. However, genetic determinants of
PCA3 expression level remain unknown. To investigate the association between genetic variants and PCA3 mRNA
level, a genome-wide association study was conducted in 1371 men of European descent in the REduction by
DUtasteride of prostate Cancer Events trial. First-voided urine specimens containing prostate cells were obtained after
digital rectal examination. The PROGENSA PCA3 assay was used to determine PCA3 score in the urinary samples.
A linear regression model was used to detect the associations between (single nucleotide polymorphisms) SNPs
and PCA3 score under an additive genetic model, adjusting for age and population stratification. Two SNPs,
rs10993994 in β-microseminoprotein at 10q11.23 and rs10424878 in kallikrein-related peptidase 2 at 19q13.33, were
associated with PCA3 score at genome-wide significance level (P= 1.22 × 10−9 and 1.06 × 10−8, respectively). Men
carrying the rs10993994 “T” allele or rs10424878 “A” allele had higher PCA3 score compared with men carrying
rs10993994 “C” allele or rs10424878 “G” allele (β = 1.25 and 1.24, respectively). This is the first comprehensive
search for genetic determinants of PCA3 score. The novel loci identified may provide insight into the molecular
mechanisms of PCA3 expression as a potential marker of PCa.
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Introduction
Prostate cancer (PCa) is the most prevalent noncutaneous malignancy
and the second leading cause of cancer mortality in the United States
[1]. Prostate-specific antigen (PSA) is the most commonly used
screening tool for PCa. PSA screening has led to progress in early
detection [2]. However, elevated serum PSA is regularly detected in
benign prostate disorders such as prostatitis and benign prostatic hyper-
plasia (BPH), resulting in a relatively high rate of unnecessary PSA-
triggered biopsies [3].
Compared to PSA, prostate cancer gene 3 (PCA3) is more specific
for PCa. PCA3 is a prostate-specific non-coding mRNA that is over-
expressed in prostate tumor tissue and metastases and is not observed
in conjunction with benign prostate disorders such as prostatitis or
enlarged prostate [4]. Using PCA3, prostate tissue specimens con-
taining less than 10% of cancer cells can be accurately discriminated
from noncancer tissue [4]. PCA3 score is generated from the ratio of
PCA3 mRNA level to PSA mRNA level, through which PCA3 expres-
sion is normalized with the PSA expression used as a housekeeping
gene. Recently, several independent studies have shown that PCA3
score has better performance than PSA in predicting prostate biopsy
outcome in subjects with elevated PSA (>2.5 ng/ml) [5–8]. PCA3
score was also observed to be indicative of biopsy Gleason score in the
REduction by DUtasteride of prostate Cancer Events (REDUCE) trial
[9] and another study in a multidescent population by Nakanishi et al.
[10]. Moreover, PCA3 was correlated with prostate tumor size [10].
Despite the well-characterized clinical use of PCA3, our knowledge
of the genetic determinants of PCA3 expression levels is negligible. In
this study, we conducted a genome-wide association study (GWAS) to
identify SNPs that are associated with the urine level of PCA3 in the
REDUCE trial.
Materials and Methods
Study Population
Subjects in ourGWASwere originally enrolled in theREDUCE trial,
a 4-year multicenter, randomized, double-blind, placebo-controlled
clinical study to evaluate the effect of dutasteride on the risk of
PCa in men. Individuals participating in this trial had to meet the
following criteria: 1) age between 50 and 75 years; 2) prostate volume
(PV) ≤80 cm3; 3) PSA level of 2.5 to 10 ng/ml for subjects <60 years
old and 3 to 10 ng/ml for those ≥60 years; 4) negative biopsy (within
6 months of enrollment) for PCa, high-grade prostatic intraepithelial
neoplasia, or atypical small acinar proliferation [11].
In the REDUCE trial, a total of 1649 individuals of European descent
(885 in the placebo and 764 in the dutasteride treatment arms) had avail-
able PCA3 measurement. Among them, 162 of 885 subjects (18.3%) in
the placebo and 116 of the 764 subjects (15.2%) in the dutasteride arm
were diagnosed with PCa in the 4-year follow-up. The remaining 1371
individuals (723 in the placebo arm and 648 in the dutasteride arm) with
negative prostate biopsy were included for further GWAS analysis.
Characteristics of the 1371 individuals are summarized in Table W1.
Measurement of PCA3 and PSA mRNA Levels
First-voided urine specimens containing prostate cells were obtained
after digital rectal examination before year 2 and 4 biopsies. The
PROGENSA PCA3 Assay was used to measure PCA3 and PSAmRNA
levels in the urinary samples at an independent laboratory (Caris Life
Sciences/Molecular Profiling Institute, Phoenix, AZ) [12]. The first avail-
able PCA3 and PSA value (at year 2 or year 4) was used in our analysis.
Genotyping, Imputation, and Quality Control
Genotyping was conducted using an Illumina HumanOmniExpress
BeadChip system (729,755; single nucleotide polymorphisms [SNPs]
included) at the Center for Cancer Genomics, Wake Forest University
School of Medicine. Samples with a genome-wide call rate≥95% were
included in subsequent GWAS analysis. For SNPs, the quality control
criteria were as follows: minor allele frequency >0.01, genotype call rate
>95%, and Hardy-Weinberg Equilibrium >0.001. The remaining
586,462 SNPs were used to impute the genotypes of SNPs that were
not directly genotyped in the genome, by IMPUTE software [13] using
combined data of the 1000 Genomes low-coverage pilot project and
HapMap3 data as references (www.1000genomes.org and www.hapmap.
org). The same quality control and a posterior probability of >90%was
applied to imputed SNP calls.
Personalized PCA3 Score and Cutoffs
Personalized PCA3 score and cutoff were calculated for each
individual. First, a linear regression model was fitted, where log-
transformed PCA3 scores were treated as outcomes and the number
of alleles associated with higher PCA3 scores was treated as covari-
ates. Genetic effects were calculated for three genotypes (aa, Aa, and
AA), using the fitted values. Relative allelic effects (percentage of
increase per allele) were calculated by dividing the fitted values of aa
and Aa. The relative risk to the population for each genotype was then
computed on the basis of the relative allelic effect and genotypic
frequency. Second, assuming a multiplicative model, the combined
Figure 1.Manhattan plot of genome-wide association analyses for PCA3 score in 1371 subjects with negative prostate biopsy. The x-axis
represents chromosomal position; the y-axis represents−log10 P values from linear regression. The red horizontal solid line indicates the
preset threshold of P = 1 × 10−8.
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relative genetic effect was calculated by multiplying the relative geno-
typic effect for each SNP relative to the general population. Third, a
personalized PCA3 score for each subject was determined by dividing
the raw PCA3 score by the combined relative genetic effect, while the
personalized cutoff for each subject was generated by multiplying a uni-
form cutoff of 35 by the combined relative genetic effect.
Statistical Analysis
We calculated PCA3 score as follows: PCA3 mRNA copy number/
PSA mRNA copy number × 1000. PSA mRNA copy number here
was used to correct for the number of prostate cells present in urine
sample. PCA3 score was log transformed to approximate a normal
distribution for further analysis (Figure W1).
A linear model implemented in PLINK software package [14] was
used to detect the association of each SNP (genotyped and imputed)
with PCA3 score under an additive genetic model in 1371 subjects
negative for PCa biopsy. Principal component analysis was conducted
to detect potential population stratification by EIGENSTRAT soft-
ware [15]. Age and the top eigenvector that indicates ancestral hetero-
geneity within a group of individuals were adjusted as covariates in
multiple regression analysis. Genome-wide significance level was set
at a P value of 1 × 10−8. For regions containing more than one signif-
icant variant (P < 10−6), multiple linear regression analysis was applied
to test the independence of each SNP, adjusting for the most signif-
icant SNPs, as well as all other covariates.
Results
Urine mRNA levels of PCA3, PSA (copies per milliliter, expressed as
PCA3CPM and PSACPM, respectively), as well as the resulting PCA3
scores are summarized in Table W1. Although the median values of
PCA3CPM and PSACPM in the dutasteride arm differed from those in
the placebo arm (P < .0001), PCA3 scores were not significantly different
between dutasteride and placebo arms (Wilcoxon rank sum test, P = .72).
In the present GWAS, a total of 3,076,666 SNPs (genotyped and
imputed) were analyzed for association with log-transformed PCA3
score in 1371 subjects (placebo and dutasteride arms; Figure 1). The
inflation factor of GWAS results based on a quantile-quantile (Q-Q)
plot analysis was modest (λ = 1.01; FigureW2). Therefore, the reported
P values are not corrected for genomic inflation.
Two SNPs, rs10993994 in the β-microseminoprotein (MSMB) gene at
10q11.23 and rs10424878 in the kallikrein-related peptidase 2 (KLK2)
gene at 19q13.33, reached a genome-wide significant P value of 1.22 ×
10−9 and 1.06 × 10−8, respectively (Table 1), adjusting for age and the
top eigenvector for potential population stratification in an additive
model. Seventeen SNPs with a P value smaller than 1 × 10−6 are pre-
sented in Table W2. Several other SNPs in the MSMB gene region or
KLK2/kallikrein-related peptidase 3 (KLK3) gene cluster were significant
in the P value range of 1 × 10−6 to 1 × 10−8 (Figure 2, A and B). After
adjusting for the most significant SNPs and all other covariates, none of
the other SNPs in the MSMB or KLK2/KLK3 regions remained inde-
pendently associated with PCA3 score. No significant association
between PCa risk and the 183 SNPs within or surrounding the PCA3
gene at 9q21 (78,519,174-78,642,285, NCBI build 36) was detected.
The effects of rs10993994 and rs10424878 on PCA3 score were then
evaluated. As shown in Table 1, the least square mean values of PCA3
score were 13.35, 16.82, and 20.11 for the rs10993994 CC, CT, and
TT carriers, respectively (β = 1.25 for “T” allele). The least square mean
values of PCA3 score were 13.68, 16.61, and 20.76 for rs10424878
GG, AG, and AA carriers, respectively (β = 1.24 for “A” allele).
In addition, we examined the associations of the two top SNPs with
PCa risk, baseline PV, and International Prostate Symptom Score (IPSS;
TableW3). The SNP rs10993994was significantly associated with PCa
risk (odds ratio [OR] = 1.20, P = .02), baseline PV (β = 0.03, P = .01),
and IPSS (β = −0.27, P = .05). The SNP rs10424878 was not signifi-
cantly associated with PCa risk (OR = 1.08, P = .35) or baseline IPSS (β =
0.04, P = .76) but was associated with baseline PV (β = −0.02, P = .02).
Moreover, a personalized cutoff value of PCA3 score was estimated
for each individual. The estimated personalized cutoff ranged from
24.9 to 60.6. The estimated personalized cutoff was 24.9 for subjects
carrying both the rs10993994 CC genotype and the rs10424878 GG
genotype, while it was 60.6 for subjects carrying both the rs10993994
TT genotype and the rs10424878 AA genotype (Figure W3).
Discussion
In the present GWAS, conducted among 1371 European descent men
with negative prostate biopsies, the strongest overall effects on PCA3
score were observed for two independent genetic variants, rs10993994
in MSMB at 10q11.21 (P = 1.22 × 10−9) and rs10424878 in KLK2
at 19q13.33 (P = 1.06 × 10−8). Presently, this is the first discovery of
genetic determinants based on a genome-wide study for PCA3, one
of the most valuable early detection biomarkers for PCa.
SNP rs10993994 is located 57 bp upstream of exon 1 of the
MSMB gene, which encodes MSMB, one of the major constituents of
seminal plasma [16]. MSMB is a member of immunoglobulin binding
factor family and can act as a tumor suppressor by binding to cell surface
receptors and regulating prostate cell apoptosis through mitogen-
activated protein (MAP) kinase/AKT signaling [17]. Previous studies
discovered that the expression of MSMB is much higher in normal
and benign prostate tissues than in tumor tissues [18] and urinary
MSMB level decreases during tumorigenesis [19].
As the most thoroughly studied genetic variant in the MSMB gene
region, rs10993994 has been reported to be associated with PCa [20]
Table 1. SNPs Associated with PCA3 Score in 1371 Subjects with Negative Prostate Biopsy.
SNP Chr BP* Gene Alleles Risk Allele Mean of PCA3 Score† β (SE)‡ P ‡
Allele Freq LL LH HH
rs10993994 10 51,219,502 MSMB C/T T 0.41 13.35 16.82 20.11 1.25 (0.037) 1.22 × 10−9
rs10424878 19 56,066,779 KLK2 G/A A 0.40 13.68 16.61 20.76 1.24 (0.038) 1.06 × 10−8
*BP genomic position is based on NCBI build 36.
†The mean values of PCA3 score are back log-transformed. LL indicates homozygous carriers of the allele that is associated with a lower value of PCA3 score; LH indicates heterozygous carrier of the allele
that is associated with a lower value of PCA3 score; HH indicates homozygous carriers of the allele that is associated with a higher value of PCA3 score.
‡The P values are based on linear regression analysis on the log-transformed PCA3 score and adjusted for age and the top eigenvector assuming an additive model; β is back log-transformed, while SE is
log-transformed.
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and this association appears to be independent of age at diagnosis or
tumor grade [21]. Functional investigation revealed that the minor
allele “T” of rs10993994 was causally associated with lower expres-
sion of MSMB, because replacement of wild-type C to T altered a
cAMP response element–binding protein transcription binding site,
resulting in reduced promoter activity [22]. Fine mapping of the
MSMB promoter region did not identify other SNPs having major
effects regulating MSMB expression [22]. Taken together, these find-
ings suggest rs10993994 as a potential independent causal genetic
variant for PCa.
In our study, rs10993994 in MSMB was associated with PCA3
score, a risk factor for PCa. The T allele, associated with a decrease in
MSMB promoter activity and an increase in PCa risk, was associated
with an increase in urinary PCA3. Since rs10993994 was associated
with PCa risk in the placebo arm of REDUCE trial (OR = 1.20, P =
.02), one potential scenario is, even in this population of men screened
for PCa,menwith the T allele would bemore likely to have (undetected)
PCa and thus have a higher urinary PCA3. However, if this was the
explanation, one would expect other PCa risk SNPs (e.g., SNPs at
8q24 and HNF1B) to be associated with urinary PCA3. Except for
rs10993994, the majority of the other 32 known PCa risk–associated
SNPs [23] were not significantly associatedwith PCA3 score (P > .0016,
Bonferroni corrected for 32 tests), and only two of these documented
PCa risk SNPs, rs10486567 and rs1512268, have P values slightly
smaller than .0016 (.0005 and .0010, respectively). Therefore, it is
unlikely that rs10993994 affects PCA3 score through this mechanism.
Given that rs10993994 in MSMB is also associated with serum
PSA levels, we also considered the possibility that rs10993994 affects
PCA3 score indirectly through PSA. Additional association analysis
of PCA3 score in which urinary PSA level was adjusted as a covariate
showed that urinary PSA level had little effect on PCA3 score (P =
.84). Moreover, rs10993994 is not statistically related to serum PSA
Figure 2. Association of PCA3 score at 10q11.23 (A) and 19q13.33 (B) in 1371 subjects with negative prostate biopsy. The x-axis represents
chromosomal position; the y-axis represents−log10 P values from linear regression. Solid purple lines represent recombination rate in
cM/MB. Each plotted point represents one SNP.
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level among the 1371 subjects in our study (P = .37, adjusted for age
and the top eigenvector). Therefore, the association between
rs10993994 and PCA3 score found in our study is most likely to
be independent of PSA level in urine or in serum.
Since rs10993994 is located within an androgen receptor binding
region [24] and androgen signaling plays an important role in the
pathogenesis of PCa [25], it is possible that rs10993994 has an effect
on PCA3 score through the androgen action pathway. In the present
study, 648 of the total 1371 subjects were in the dutasteride arm.
Dutasteride is a 5α-reductase inhibitor that reduces systemic and tissue
levels of 5α-dihydrotestosterone, the principal androgen in the prostate
[25]. Therefore, we compared the effects of rs10993994 on PCA3 score
in the placebo and dutasteride arms separately. The β values of the
T allele in an additive model (adjusted for age and the top eigenvector)
in 723 placebo subjects and 648 dutasteride subjects were 1.27 and
1.24, respectively, with P values of 2.5 × 10−6 and 6.7 × 10−5. The
effects of rs10993994 on PCA3 score were quite similar in the two
arms. On the basis of these results, rs10993994 may not affect
PCA3 score through the androgen pathway.
There is still another scenario thatmay explain the association between
rs10993994 and PCA3 score. There may be some currently unknown
downstream relationship whereby the level ofMSMB expression directly
affects the production of PCA3 mRNA or its ability to get into the
urine. However, in vitro studies with PCA3-producing cell lines and
other functional studies are required to address this hypothesis.
The second SNP associated with PCA3 score, rs10424878, is about
2 kb upstream of KLK2, the coding gene of KLK2. As a member of
kallikrein gene family, KLK2 is a serine protease and can activate
urokinase-type plasminogen activator, cleave binding proteins of insulin-
like growth factor, and cleave the preform of PSA to the mature enzyme,
participating in a proteolytic cascade, which has been associated with
tumorigenesis and metastasis of PCa [26]. In addition, PCa tumor tissues
have a higher KLK2 expression level than benign tissues [27,28] and
patients with PCa were also found to have higher serum KLK2 [29,30].
Genetic variants in KLK2 were found to be associated with PCa in
candidate gene association studies [31], although no SNPs inKLK2 have
been confirmed or identified by GWAS. In our GWAS on PCA3 score,
rs10424878 and another nine SNPs in KLK2 and five SNPs in KLK3
reached a P value of 1 × 10−6. However, the associations between all of
the other 14 KLK2/KLK3 SNPs and PCA3 score no longer existed after
adjusting for rs10424878 (P > .05), indicating that rs10424878 is the
only independent SNP in KLKs that is associated with PCA3 score.
Unfortunately, little is known about the pathways or functional relation-
ships between theKLK2 and PCA3 gene. Additional association analysis
of PCA3 score in which urinary PSA level was adjusted as a covariate
showed that urinary PSA level had little effect on PCA3 score (P =
.89). We also assessed serum PSA level with rs10424878, and no asso-
ciation was found (P = .12, adjusted for age and the top eigenvector).
Overall, the effect of rs10424878 on PCA3 scores was unlikely to be
mediated through serum PSA levels.
Another possible impact of rs10424878/KLK2 on PCA3 score
could be through the androgen action pathway, since KLK2 is highly
responsive to androgens. As mentioned, androgen signaling is impor-
tant for PCa pathogenesis [25] and dutasteride could greatly reduce
5α-dihydrotestosterone levels [25]. Similar to rs10993994, we assessed
the effect of rs10424878 on PCA3 score separately in the placebo and
dutasteride arms. The β values of “A” allele in an additive model
(adjusted for age and the top eigenvector) in 723 placebo subjects only
and 648 dutasteride subjects only are 1.22 and 1.26, respectively, with
P values of 2.06 × 10−4 and 1.13 × 10−5. The effects of rs10424878 on
PCA3 score were quite similar in the two arms. Therefore, it is unlikely
that rs10424878 affects PCA3 score through the androgen pathway.
Additional biologic studies are needed to elucidate the mechanism
through which rs10424878 impacts urine PCA3 scores.
On the basis of genetic discovery, we estimated personalized PCA3
scores for 1649 subjects with PCA3 measurements, including 278 sub-
jects with positive prostate biopsy results and 1371 with negative biopsy
results. We compared the area under curve (AUC) between the model
with the raw PCA3 score and the model with the personalized PCA3
score for predicting prostate biopsy outcome. The AUCs for both
models were 0.681 and 0.682, respectively. We did not observe a statis-
tically significant difference in AUCs between the two models, which
may due to the limited number of genetic determinants identified for
the PCA3 score and the relatively small effect of each variant. Although
the personalized PCA3 scores showed limited improvement in AUC
compared with the raw PCA3 scores, the detection rate of positive pros-
tate biopsy was higher for men with 35 and higher for the personalized
PCA3 score (31.0%, 120/388) compared with the detection rate for
men with 35 and higher for the raw PCA3 score (28.3%, 119/421).
Overall, improvement in clinical use of the personalized PCA3 score
was limited in the current study. However, it may improve if more
genetic variants for PCA3 score are identified in future studies.
Two advantages of this study were its prospective design and the
stringent inclusion and exclusion criteria. Nevertheless, several limita-
tions need to be addressed. Although the most stringent Bonferroni
correction was applied to control false positive findings, our study did
not include a confirmation stage in an independent population, due
to the difficulty in identifying additional studies with available germline
DNA, PCA3 measurements, and prostate biopsy outcomes. Another
limitation is that only two SNPs were identified to be associated with
PCA3 score at a genome-wide level in this study. Therefore, further
discoveries and validations across populations are warranted.
In conclusion, this study represents the first effort to investigate
genetic determinants of PCA3 score, which may advance the under-
standing of PCA3 score. More importantly, the genetic determinants
identified might be helpful to facilitate the utilization of personalized
cutoff of PCA3 score as a marker for PCa prediction.
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Figure W1. (A) PCA3 score distribution in subjects without prostate cancer. (B) Log-transformed PCA3 score distribution in subjects
without prostate cancer.
Figure W2. Q-Q plot. Q-Q plot presenting the distribution of theoreti-
cal compared to observed −log10P for the association test results
after adjusting for top eigenvector.
Table W2. SNPs Associated with PCA3 Score, Sorted by P Value (1 × 10−6 P 1 × 10−8).
SNP Chr BP* Gene Alleles Allele† Freq‡ β (SE)§ P¶ Status
rs2739468 19 56,062,355 KLK3 A/C A 0.43 1.23 (0.038) 6.94 × 10−8 Imputed
rs1506684 19 56,063,231 KLK2 A/G A 0.43 1.22 (0.038) 1.00 × 10−7 Genotyped
rs2739461 19 56,061,263 KLK2 T/C T 0.43 1.23 (0.038) 1.00 × 10−7 Imputed
rs965537 19 56,064,609 KLK2 C/T C 0.43 1.22 (0.038) 1.10 × 10−7 Imputed
rs2739464 19 56,061,660 KLK3 G/A G 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739466 19 56,062,064 KLK3 A/G A 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739469 19 56,062,405 KLK3 T/C T 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739472 19 56,065,091 KLK2 T/C T 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739473 19 56,065,197 KLK2 A/G A 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739475 19 56,065,438 KLK2 A/G A 0.43 1.22 (0.038) 1.13 × 10−7 Imputed
rs2739476 19 56,065,630 KLK2 A/G A 0.43 1.22 (0.038) 1.39 × 10−7 Imputed
rs2739459 19 56,060,886 KLK3 G/A G 0.42 1.22 (0.038) 1.89 × 10−7 Imputed
rs2889829 9 27,600,657 C9orf72 A/G G 0.64 0.82 (0.038) 2.13 × 10−7 Genotyped
rs1997563 19 56,065,002 KLK2 T/C T 0.43 1.22 (0.038) 2.28 × 10−7 Imputed
rs2926494 10 51,187,362 MSMB T/C T 0.46 1.21 (0.038) 3.00 × 10−7 Genotyped
rs2569739 19 56,064,207 KLK2 C/T C 0.43 1.21 (0.038) 4.74 × 10−7 Imputed
rs62531686 8 1,710,268 FLJ45872 T/C C 0.3 0.83 (0.038) 8.04 × 10−7 Imputed
*BP genomic position is based on NCBI build 36.
†Allele shown here is the one with elevated PCA3 score.
‡Freq is the frequency of Allele†.
§β Values are back log-transformed, while SE is log-transformed.
¶P values are based on linear regression analysis on the log-transformed PCA3 score and adjusted for age and the top eigenvector assuming an additive model.
Table W3. Associations between rs10993994 and rs10424878 and PCa Risk, Baseline
PV, and IPSS.
SNP Alleles (M/m) PCa Risk* Baseline PV† Baseline IPSS†
OR P β (SE) P β (SE) P
rs10993994 C/T 1.20 .02 0.03 (0.01) .01 −0.27 (0.14) .05
rs10424878 G/A 1.08 .35 −0.02 (0.01) .02 0.04 (0.14) .76
*Association analysis for PCa risk was conducted in the placebo arm of the REDUCE
trial using logistic regression.
†Association analyses for baseline PV and IPSS were conducted in both the placebo and
dutasteride arms of the REDUCE trial using a linear regression model assuming additive
effects of the minor alleles (0, 1, and 2). PV and IPSS were treated as continuous variables.
Figure W3. Cumulative distributions of the personalized cutoff of
PCA3 score. The x-axis represents the percentile of the population
and the y-axis represents the personalized cutoff of PCA3 score,
which is adjusted by the genotypes of rs10993994 and rs10424878.
Red lines stand for subjects with positive prostate biopsy; blue lines
stand for subjectswith negativeprostate biopsy; green lines stand for
all the subjects.
